Field effectiveness of vaccination against tick-borne encephalitis

被引:202
作者
Heinz, Franz X.
Holzmann, Heidemarie
Essl, Astrid
Kundi, Michael
机构
[1] Med Univ Vienna, Inst Virol, AT-1095 Vienna, Austria
[2] Fessel GfK Inst Hlth Care, Vienna, Austria
[3] Med Univ Vienna, Ctr Publ Hlth, Inst Environm Hlth, Vienna, Austria
关键词
tick-borne encephalitis (TBE); vaccine effectiveness; vaccination coverage;
D O I
10.1016/j.vaccine.2007.08.024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Tick-borne encephalitis (TBE) is a vaccine-preventable disease caused by a flavivirus (TBE virus) that is endemic in many European countries and large parts of Central and Eastern Asia. In Europe, highly purified formal in -inactivated whole virus vaccines are in widespread use, but the vaccination coverage differs significantly between countries with TBE endemicity. Austria presents an exceptional situation because 88% of the total population have a history of TBE vaccination, with 58% being regularly vaccinated within the recommended schedule. In this study, we investigated the field effectiveness of TBE vaccination in Austria for the years 2000-2006 in different age groups on the basis of the documented numbers of hospitalized cases in unvaccinated and vaccinated people and the sizes of these population groups as revealed by representative inquiries. We show that the overall effectiveness in regularly vaccinated persons is about 99% with no statistically significant difference between age groups. It is at least as high after the first two vaccinations, i.e. before the completion of the basic vaccination scheme by a third vaccination, but is significantly lower (about 95%) in those with a record of irregular vaccination. Our data confirm the excellent performance of TBE vaccine under field conditions and provide evidence that, in Austria, about 2800 cases were prevented by vaccination in the years 2000-2006. (D 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7559 / 7567
页数:9
相关论文
共 50 条
[1]  
Dooley Samuel W., 2008, Morbidity and Mortality Weekly Report, V57, P1
[2]  
[Anonymous], FIELDS VIROLOGY
[3]   History of TBE vaccines [J].
Barrett, PN ;
Schober-Bendixen, S ;
Ehrlich, H .
VACCINE, 2003, 21 :S41-S49
[4]  
BARRETT PN, 2004, VACCINES, P1039
[5]   Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice [J].
Ben-Nathan, D ;
Lustig, S ;
Tam, G ;
Robinzon, S ;
Segal, S ;
Rager-Zisman, B .
JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (01) :5-12
[6]  
BURKE DS, 2006, FIELDS VIROLOGY, P1043
[7]   Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes [J].
Chang, KC ;
Tseng, CD ;
Chou, TF ;
Cho, YL ;
Chi, TC ;
Su, MJ ;
Tseng, YZ .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2006, 36 (01) :1-7
[8]   Nationwide hepatitis B vaccination program in Taiwan: Effectiveness in the 20 years after it was launched [J].
Chien, Yin-Chu ;
Jan, Chyi-Feng ;
Kuo, Hsu-Sung ;
Chen, Chien-Jen .
EPIDEMIOLOGIC REVIEWS, 2006, 28 :126-135
[9]   B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus [J].
Diamond, MS ;
Shrestha, B ;
Marri, A ;
Mahan, D ;
Engle, M .
JOURNAL OF VIROLOGY, 2003, 77 (04) :2578-2586
[10]   Tick-borne encephalitis [J].
Dumpis, U ;
Crook, D ;
Oksi, J .
CLINICAL INFECTIOUS DISEASES, 1999, 28 (04) :882-890